Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Kidney cancer

Tivozanib monotherapy outperforms combination therapy in post-ICI RCC

Nature Reviews Urology volume 21, page 706 (2024)Cite this article

Subjects

The multicentre, randomized, phase III trial TiNivo-2 was conducted to assess the efficacy of the vascular endothelial growth factor receptor inhibitor tivozanib alone versus in combination with the immune checkpoint inhibitor (ICI) nivolumab in patients with advanced renal cell carcinoma (RCC) who had progressed during or after 1–2 previous lines of therapy including one ICI. Progression-free survival (PFS) was higher in patients in the monotherapy group (7.4 months) than in patients receiving combination therapy (5.7 months; HR 1.10, 95% CI 0.84–1.43; P = 0.49). These results show that re-challenging patients with advanced RCC with ICI therapy is not advisable and suggest tivozanib monotherapy as a viable treatment option in the post-ICI setting.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

References

Original article

  • Choueiri, T. K. et al. Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 study. Lancet 404, 1309–1320 (2024)

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Nature Reviews Urology https://www.nature.com/nrurol/

    Maria Chiara Masone

Authors
  1. Maria Chiara Masone
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Maria Chiara Masone.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Masone, M.C. Tivozanib monotherapy outperforms combination therapy in post-ICI RCC. Nat Rev Urol 21, 706 (2024). https://doi.org/10.1038/s41585-024-00971-y

Download citation

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41585-024-00971-y

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing